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Objective: To identify the characteristics of CF patients with hemoptysis in Israel and to compare clinical features and risk factors to a control
group of CF patients without hemoptysis.
Design: Retrospective chart review.
Patients: All CF patients in Israel who experienced hemoptysis between 2001 and 2005 and a control group of sex- and age-matched patients with
no history of hemoptysis.
Results: 40/440 CF patients (9.1%) experienced hemoptysis during the study period, 50% were male. Ten patients (25%) were under 13 years old
at the first hemoptysis episode. Pulmonary exacerbation was the precipitating factor in 90%. Twenty three patients showed moderate or major
hemoptysis. 35/40 patients responded well to conservative therapy. Bronchial artery embolization (BAE) was performed in 5 patients with no
recurrence of bleed within 24 h. However all of these patients experienced recurrent hemoptysis. One patient died during the follow-up period
because of end stage lung disease. Pulmonary function tests, body-mass index, coagulation tests, pancreatic status, presence of bronchiectasis,
sputum cultures and genetic mutations were similar in the two groups. A high incidence (57.5%) of associated diseases including cystic fibrosis
related diabetes, cirrhosis and portal hypertension, and distal intestinal obstruction syndrome was found among hemoptysis patients, compared to
only 5.2% in the control group (pb0.001).
Conclusions: Hemoptysis, even major, did not seem to be a risk factor for mortality in our patients. A higher incidence of hemoptysis was found in
our pediatric patients compared to other series. BAE shows a high immediate rate of success in controlling hemoptysis, but does not prevent future
disease.
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Over the past two decades the survival rate of CF patients has
increased significantly. Consequently, the number of cystic⁎ Corresponding author. Pediatric Pulmonology Unit, Chaim Sheba Medical
Center, Tel Hashomer 52621, Israel; Tel./fax: +972 3 5345914.
E-mail address: ori.efrati@sheba.health.gov.il (O. Efrati).
1569-1993/$ - see front matter © 2007 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2007.11.007fibrosis patients who develop pulmonary complications has
increased, in parallel with increases in life expectancy [1].
Hemoptysis, one of these complications, occurs in up to 60% of
CF patients over 18 years of age, as the pulmonary disease
progresses [2,3,4].
Major or massive hemoptysis, a potentially life threatening
complication, has a yearly incidence of 1% in CF individuals
aged 16–20 years [1,5]. Massive hemoptysis is associated withd by Elsevier B.V. All rights reserved.
Table 1
Clinical status, bleeding characteristics and treatment of patients with major/massive
hemoptysis
Patient
#
Age
onset
FEV1
(% predicted)
BMI
(kg/m²)
Associated
diseases
Frequency a Treatment
1 19 57 19 Cholestasis
gastritis
arthritis
1 BAE
7 13 21 21.5 – 1 BAE X 2
10 11 58 20.1 CFRD
Nutritional
failure PEG
2 BAE
15 19 64 15.7 PHT CFRD 2 BAE
18 22 35 16.9 Nutritional
failure
1 BAE X 2
23 18 55 PHT CFRD
P–S Shunt
Kidney
transplant
2 Conservative
therapy
24 42 70 26.5 – 3 Conservative
therapy
30 18 90 21.9 – 2 Conservative
therapy
32 21 61 24.5 – 2 Conservative
therapy
a Frequency: 1— more than once a month; 2— once a month to once a year;
3— less than once a year.
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and increased mortality [6] and should therefore be treated
immediately.
Minor bleeding is not life threatening, but may indicate a
pulmonary exacerbation requiring appropriate therapy.
Hemoptysis in CF patients is nearly always of arterial origin,
in particular bronchial arteries and their branches [7]. Angio-
graphic evaluation of these vessels shows dilated, tortuous and
newly developed arteries as well as bronchial-pulmonary artery
anastomoses, found mainly in areas of bronchiectasis and
chronic infection [5,8,9].
Hemoptysis can be managed in several ways, ranging from
conservative medical management to bronchial artery emboli-
zation (BAE) and surgery [10], depending on the quantity of
bleeding, urgency, and the patient's basic health status.
Although hemoptysis in CF patients has been reviewed
extensively, risk factors for the development of hemoptysis have
not been clearly identified to date, and the optimal management
is still controversial. Therefore, our goals in this study were:
A. To review our experiencewith hemoptysis in all CF patients
in Israel and to identify the patients' characteristics.
B. To compare the group of CF patients who experienced
hemoptysis to a control group of sex- and age-matched
CF patients without hemoptysis, regarding survival,
disease severity, clinical characteristics and risk factors
for hemoptysis.
2. Methods
We conducted a retrospective chart review of all CF patients
included in the Israeli CF registry who were diagnosed with
hemoptysis between January 2001 and December 2005. The
diagnosis of CF was made by the presence of typical respiratory
disease or pancreatic insufficiency, together with abnormal
sweat tests (chloride N60 mmol/L) or the presence of two CFTR
mutations. Patients with atypical CF were not included in this
study.
The study was approved by the institutional ethics committee.
To assess the influence of hemoptysis on long term survival
and severity of disease, the study group was compared to a
control group of CF patients, matched for age and sex, with no
history of hemoptysis events.
The hemoptysis group was divided into three sub-groups,
based on the amount of expectorated blood:
1. Minor hemoptysis.
2. Moderate hemoptysis (50–240 ml).
3. Major hemoptysis (N240 ml in 24 h; or recurrent bleeding of
a substantial volume over a short period of time (days); or a
large amount of blood which could be life threatening
because of asphyxiation or exsanguination [1]).
2.1. Initial management
There are no evidence-based guidelines to support most of
the therapeutic options for treating hemoptysis in CF patients.Hemoptysis was treated according to guidelines presented in the
CFF Consensus Conference Report [7].
Patients were treated with IV antibiotics if pulmonary
exacerbation was suspected. A complete blood count and
coagulation studies were performed, and intramuscular
vitamin K and tranexamic acid were administered in patients
suffering from major hemoptysis. Chest physiotherapy was
discontinued until bleeding stopped (24–48 h). When life-
threatening bleeding or massive hemoptysis occurred, some
of the patients underwent bronchial artery embolization
(BAE).
2.2. Clinical assessment
Pulmonary infection or exacerbation was defined as
hemoptysis accompanied by increased cough, a change in
sputum production, shortness of breath, decreased Forced
Expiratory Volume in the first second (FEV1, % predicted),
decreased exercise tolerance and fatigue, new crackles in
physical examination or a new sputum culture positive for
Pseudomonas aeruginosa [11].
Severity of lung disease was assessed by FEV1 [12]. The data
collected were the mean percentages of predicted value for at
least 3 different measurements obtained on routine clinical
examination in the same year or in the year preceding the
hemoptysis event. Mild lung disease was defined as FEV1 N60%
of predicted, moderate lung disease as 40–59% of predicted, and
severe lung disease as less than 40% of predicted values [13].
In order to evaluate lung disease severity and presence of
bronchiectasis chest X-rays and CT scans were reviewed by the
attending pulmonologist or a pediatric radiologist.
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Index (BMI), using the mean BMI in the year prior to the
hemoptysis event, as recorded on routine clinical examination.
2.3. Data analysis
Statistical methods used were as follows:
Pearson Chi-Square analysis for type of genetic mutation,
frequency of hemoptysis, amount of bleeding, stress caused
by bleeding and color of blood.
Fisher's Exact Test for patients' gender, pancreatic suffi-
ciency, steroidal treatment, DNAase treatment and asso-
ciated diseases.
t-test for comparison between the hemoptysis group and the
control group regarding age of patients, age onset of first
hemoptysis, BMI, lung function tests and blood coagulation
tests.
3. Results
Hemoptysis occurred in 40 out of 440 CF patients (9.1% of
all CF patients in Israel) during the study period. The mean age
of these patients at the end of the study was 25.9±8. 5 years.
Twenty patients were male (50%).Fig. 1. Clinical data for CF patients in hemoTen patients were children under the age of 13 years when
the first episode of hemoptysis occurred (25% of hemoptysis
patients or 2.3% of all CF patients in Israel). The mean age at
the first episode of hemoptysis was 18.4±7. 4 years.
Our patients survived 1–20 years after the initial hemoptysis
event. One patient expired during the follow-up period because
of end stage lung disease. Death was not associated with the
hemoptysis event.
The control group included 58 CF patients with no history
of hemoptysis. The mean age of the control group was 21±
10. 1 years.
The most common precipitating factor for a hemoptysis
event was exacerbation of a pulmonary infection (36/40, 90%).
In 3 patients the bleeding started after physical activity, in one
during sexual activity, and in one during menses.
Eight patients (20%) experienced a high frequency of
hemoptysis events (more than once a month), 24 (60%)
experienced moderate frequency (once a month to once a
year) and 8 experienced low frequency of events (less than once
a year).
17/40 (42.5%) patients showed minor or streaky hemoptysis,
13/40 (32.5) moderate hemoptysis and 9/40 (22.5%) massive
hemoptysis (Table 1).
No bronchoscopies were performed for localization of
bleeding.ptysis group compared to control group.
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tive medical therapy, in 30 of these bleeding resolved within
2–4 days, while the other 5 patients experienced persistent
bleeding for 5–7 days.
Three patients (7.5%) required blood transfusion due to
severe blood loss.
Angiography and BAE were performed 7 times in only 5 of
the 9 patients with major or massive hemoptysis, and was
withheld in 5 patients in whom bleeding stopped spontaneously
under conservative treatment.
Immediate success rate after BAE (no recurrence of bleeding
within 24 h of the procedure) was 100%.
All patients tolerated the procedure without major complica-
tions; however all of them reported chest pain during the 24 h
following the procedure and 2 had fever that lasted 24 h.
All 5 patients who underwent BAE had recurrent hemoptysis
episodes (streaky to moderate) during the follow-up period, and
2 of these patients required additional embolizations.
No patients underwent surgical procedures such as segmen-
tectomy, lobectomy or pneumonectomy to control hemoptysis.
We observed a very high prevalence (57.5%) of associated
disease such as portal hypertension (PHT) or CF-related
diabetes (CFRD) in the hemoptysis group, compared to only
5.2% in the control group (pb0.001). Specifically, cirrhosis
occurred in 12.5% of the hemoptysis group compared to only
1.7% in the control group (p=0.04). In the hemoptysis group 1
patient underwent liver transplantation during the study period,
while in 2 patients portocaval shunts were performed due to
PHT. In the hemoptysis group 5 patients (12.5%) were fed
through percutaneous endoscopic gastrostomy (PEG) compared
to only 1 patient in the control group (p=0.04).
We found no differences between the hemoptysis group and
the control group in the severity of lung disease, as reflected
either by FEV1 values (Fig. 1) or by the presence of
bronchiectasis on chest CT and X-Ray images (39/40 and
53/58, respectively).
We found a very high prevalence of positive Pseudomonas
aeruginosa cultures in both groups (100% in the hemoptysis
group and 93% in the control group).
NontuberculousMycobacterium (NTM)was identified in 5/40
patients in the hemoptysis group and in 11/58 patients in the
control group (NS); 2 and 3 patients respectively were identified
with Mycobacterium abcessus species.
There was no significant difference regarding genetic
mutations between the two groups. In the hemoptysis group
we found 20/40 patients positive for the ΔF508 mutation
compared to 26/58 patients in the control group. 17/40 patients
in the hemoptysis group were positive for W1282X mutation
compared to, again, 26/58 in the control group.
12.5% in the hemoptysis group were homozygous for
W1282X while only 8.6% in the control group were homo-
zygous for the same mutation.
There was no significant difference in pancreatic sufficiency
status, coagulation tests, BMI, or the use of DNAase inhalations
in the hemoptysis group compared to the control group (Fig. 1).
None of the patients included in the study (hemoptysis group
as well as controls) was diagnosed with ABPA.4. Discussion
Hemoptysis, even mild, may be a warning sign for im-
pending major hemoptysis or an indicator of pulmonary
infection or exacerbation. Massive hemoptysis is not only an
alarming clinical event but is also considered to signify a very
poor prognosis [6].
According to our data, 40 (9%) patients out of the 440
patients in the Israel CF registry experienced hemoptysis.
Seventeen patients (3.9%) experienced minor hemoptysis, 13
(2.9%) showed moderate hemoptysis, and 9 patients out of all of
the CF population (2.0%) experienced major hemoptysis. The
prevalence of major or massive hemoptysis in our study was
similar to the prevalence described in the North American
registry (4%) [14], and lower than that reported in Australia
(6%) [15]. However, our results probably underestimate the
incidence of hemoptysis in Israel, as only patients who
experienced hemoptysis during the 5 year study period were
included.
Blood-tinged sputum is a rare occurrence in children, in
whom hemoptysis may go unnoticed because they tend to
swallow their sputum [15,16].
Coss-Bu et al. [17] found a low incidence of hemoptysis in
pediatric patients, and suggested that hemoptysis is a late
complication of CF affecting primarily those patients who
survive into adolescence and adulthood. Conversely, our data
show that hemoptysis appears much earlier in Israeli CF
patients, than in other parts of the world [17]. In our study,
hemoptysis occurred in 10 patients before age 13 —
corresponding to 25% of CF patients with hemoptysis and
2.3% of all CF patients in Israel. A specific CFTR mutation
unique to our region, or other genetic factors, such as vascular
growth factors allowing the development of enlarged and
tortuous vessels under the influence of inflammation, may
explain these differences [18,19].
Most episodes of hemoptysis appear to be associated with
pulmonary infection and exacerbation [1]. Accordingly, in our
study the most important precipitating factor was pulmonary
exacerbation (90% of all hemoptysis events). Other trigger-
ing factors were physical activity (3 patients), sexual activity
(1 patient), and menses (1 patient). We assume that in these
patients, the bleeding event was a consequence of upper and
lower airway irritation, resulting from excessive breathing
efforts, or from a neuro-hormonal stress reaction.
Holsclaw et al. [6] claimed that massive hemoptysis was
associated with severe diffuse lung disease. In our study, 8 out
of the 9 patients who experienced massive hemoptysis had mild
or moderate lung disease, similarly to Barben et al. [15] who
found no association between the severity of lung disease and
the occurrence of major hemoptysis. This finding can be
explained by extensive localized damage with focal areas of
dilated tortuous arteries that may result in massive bleeding,
even following a minor trigger like coughing, retained
secretions, or infection.
Similarly to previous studies, most patients with hemoptysis
in our study (87.5%) were treated successfully using con-
servative medical management, intended to control pulmonary
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antibiotics, tranexamic acid, and vitamin K. Of note, vitamin K
was administered even when coagulation tests were normal,
assuming that vitamin K deficiency can exist even in the
presence of normal PT and PTT [1,20]. Bleeding in our patients
stopped after a maximum of 7 days under conservative therapy.
Five of 9 patients with major hemoptysis underwent
BAE. Data from previous studies showed a high success rate
(90–95%) for BAE in controlling hemoptysis [10,13,21,22].
However, Antonelli et al. [21] found that BAE did not change
the clinical course of the disease and FEV1 values. This was
true for our study group as well: our immediate success rate,
defined as no recurrence of bleeding within 24 h of the
procedure, was complete (100%). However, hemoptysis
recurred in all patients one week to one year following the
procedure. Two patients required two further BAE procedures,
and BAE did not affect the number of pulmonary exacerbations,
FEV1 values, or the frequency of subsequent hemoptysis
episodes.
Reported complications of BAE include fever, chest pain,
dysphagia, bronchial necrosis, bowel ischemia, paraplegia as a
result of embolization of the spinal artery and transverse
myelitis, and death [10,15,23–27]. In contrast, in our study,
only minor complications such as fever (2 patients) and chest
pain (5 patients) that subsided within 24 h, were observed.
Major hemoptysis has been reported to be associated with
immediate mortality [15] as well as with increased 2-year
mortality [14]. However, in our study, all patients with massive
hemoptysis are alive 5–10 years following the initial event of
massive hemoptysis.
Bronchoscopy may be performed in order to localize the
source of the bleeding, or rarely, to stop the bleeding. In our
experience, conservative treatment or BAE resulted in cessation
of bleeding in all patients, and thus we did not find
bronchoscopy necessary.
To evaluate risk factors for developing hemoptysis and to
compare the disease severity and patient characteristics, we
selected a control group of CF patients, matched for age and
sex, with no manifested episodes of hemoptysis. There were
no differences between the hemoptysis group and the controls
regarding clinical features such as FEV1, BMI, pancreatic
sufficiency status, the detection rate of Pseudomonas
aeruginosa in sputum cultures, or the presence of Mycobac-
terium species [28].
Malabsorption of fat-soluble vitamin K, as well as liver
cirrhosis, may predispose CF patients to coagulation defects.
However, in our study, coagulation tests were within the normal
range in both patient groups.
There was no difference between the two patient groups
regarding the severity of lung disease and presence of
bronchiectasis on chest X-Rays and CT scans.
It has been suggested that DNAase (Pulmozyme©) inhala-
tions are associated with hemoptysis [29]. However, at the time
of the study there was no difference between the groups
regarding DNAase treatment.
Our hemoptysis group had a high prevalence of CF-
associated diseases (CFRD, PHT and nutritional deficiency).This may suggest that patients who present with hemoptysis are
less healthy overall than those who do not. Unlike the data from
the US registry [14], in our study liver cirrhosis was
significantly more prevalent in patients with hemoptysis
compared to controls. It could be argued that the high
prevalence of associated diseases could reflect ascertainment
bias, however, all of the patients included in the study
underwent evaluation for liver disease and screening for
CFRD as part of their routine care, according to the CFF
guidelines, whether they had hemoptysis or not.
In conclusion, in our patients, hemoptysis, even massive, did
not seem to be a major risk factor for mortality. We found a
higher incidence of hemoptysis in our pediatric population
compared to other CF populations. BAE shows a high
immediate rate of success in controlling hemoptysis, but does
not change the course of the underlying disease. Except for the
difference in the incidence of associated diseases, especially
CFRD and liver cirrhosis, we could not identify any predis-
posing factor for hemoptysis. Further multicenter studies are
needed to evaluate risk factors, pathogenesis and treatment for
hemoptysis in CF patients.
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